Teva Pharmaceutical Industries (TEVA) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Strategic framework and growth pillars

• Four-pillar strategy focuses on innovation, generics, capital allocation, and execution, aiming for sustained multi-year growth.

• Emphasis on disciplined OpEx management while increasing investment in pipeline and key products to drive EBITDA growth through 2027 and beyond.

• Revlimid revenue expected to end in 2026, with mitigation plans via biosimilars and complex generics to offset headwinds.

Key product and pipeline updates

• Austedo projected to reach $2.5B in 2027, with IRA impact already factored into guidance; growth driven by large untreated patient population and improved adherence.

• TL1A phase II readout for ulcerative colitis and Crohn's expected by year-end, with phase III planned for 2025 pending results; study design based on robust placebo assumptions.

• Long-acting olanzapine study to complete by year-end, with data presentation and regulatory submission targeted for 2024–2025 and a potential 2026 launch.

Market opportunities and differentiation

• ICS/SABA inhaler leverages device expertise, targeting a large unmet need in asthma with a differentiated, easy-to-use product; phase III readout expected in H2 2026.

• Anticipates significant market creation by competitors, with differentiation in pediatric indications and device simplicity.

• Celiac and vitiligo studies progressing, with endoscopy-based celiac trial starting in Q1 2024 and vitiligo enrollment ongoing.